Viridian Therapeutics, Inc. (VRDN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 40/100 (MEDIUM), 6.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.44% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
- Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
- Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
- Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
- Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)
- Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?
- Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Viridian Therapeutics, Inc..
Full VRDN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.